Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 8218 results

  1. Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Cyanoacrylate glue for hernia mesh fixation (MT707)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. O2Matic pro 100 (MT746)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Subcutaneous pembrolizumab with platinum-based chemotherapy for untreated metastatic non-small-cell lung cancer [TSID12213]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Oral cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12214]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Long-acting injections of cabotegravir with rilpivirine for treating HIV-1 in people 12 to 17 years [TSID12219]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  10. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Psoriasis: assessment and management (CG153)

    In development Reference number: GID-NG10448 Expected publication date: TBC

    NICE guideline
    In development

  13. Technologies to improve the detection of endometrial cancer

    Topic prioritisation

    Health technology evaluations
    Topic prioritisation

  14. Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081

    Awaiting development Reference number: GID-TA11705 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Henlius (pertuzumab biosimilar) for treating HER2-positive breast cancer [TS ID 12094]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation